CASTLE BIOSCIENCES INC

Item 5. Other Information.

On March 5, 2025, Kristen Oelschlager, our Chief Operating Officer, terminated a trading arrangement for the sale of the Company’s common stock. Such trading arrangement was intended to satisfy the affirmative defense conditions of the Securities Exchange Act Rule 10b5-1(c), but complied with the then applicable requirements of Rule 10b5-1(c) when adopted in March 15th, 2024. Such trading arrangement provided for the sale of up to 31,585 shares between July 1, 2024 and June 30, 2025. Also, on March 6, 2025, Ms. Oelschlager adopted a Rule 10b5-1 trading arrangement providing for the sale from time to time of an aggregate of up to 44,287 shares of our common stock. The new trading arrangement is intended to satisfy the affirmative defense in Rule 10b5-1(c). The duration of the trading arrangement is estimated to be from June 6, 2025 until the earlier of all transaction under the trading arrangement being completed or June 30, 2026.

On March 14, 2025, Frank Stokes, our Chief Financial Officer, adopted a Rule 10b5-1 trading arrangement providing for the sale from time to time of an aggregate of up to 6,738 shares of our common stock and 25,137 options shares. The new trading arrangement is intended to satisfy the affirmative defense in Rule 10b5-1(c). The duration of the trading arrangement is estimated to be from June 10, 2025 until the earlier of all transaction under the trading arrangement being completed or July 31, 2025.

No other officers or directors, as defined in Rule 16a-1(f), adopted and/orterminated a Rule 10b5-1 trading arrangement or a non-Rule 10b5-1 trading arrangement, as defined in Regulation S-K Item 408, during the last fiscal quarter.